ALNY · Alnylam Pharmaceuticals, Inc.
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Jul 30, 2026TL;DR. Alnylam reported Q2 2026 total net product revenues of $1,172 million (74% growth), with TTR revenues surpassing $1 billion for the first time, driven by Amvutra demand. The company lowered full-year 2026 TTR net product revenue guidance to $4,200–$4,500 million (from $4,400–$4,700 million) due to normalization of second-line demand, while raising collaboration and royalty revenue guidance by $150 million at the midpoint to $575–$625 million.
- + Total net product revenues grew 74% to $1,172 million in Q2 2026, with TTR revenues exceeding $1 billion for the first time
- + Raised full-year 2026 collaboration and royalty revenue guidance by $150 million at midpoint to $575–$625 million
- + Non-GAAP operating income more than tripled year-over-year to $318 million
- − Lowered full-year 2026 TTR net product revenue guidance to $4,200–$4,500 million, a $200 million reduction at the midpoint
- − Gross margin on product sales declined to 75%, down 4 percentage points year-over-year due to higher Sanofi royalty rates on Amvutra
- − Non-GAAP R&D expenses increased 38% year-over-year to $377 million driven by three ongoing Phase 3 trials
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ALNY
this stock
Alnylam Pharmaceuticals, Inc.
|
$34.17B | -38.0% | +22.9% | — | 5.4% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +15.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -1.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +553.0% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ALNY | +0.1% | +0.3% | -23.2% | +2.5% | -38.0% |
| SPY | -0.7% | +0.1% | +12.2% | -0.6% | +11.8% |
| vs SPY | +0.8% | +0.2% | -35.4% | +3.1% | -49.8% |